Royalty Pharma RPRX Total costs & expenses

Total costs & expenses at other companies

Ligand PharmaceuticalsLGND

$34.35M-57.9%

BridgeBio PharmaBBIO

$300.47M+36.0%

Rigel PharmaceuticalsRIGL

$46.93M+15.7%

ALN

Alnylam PharmaceuticalsALNY

$1.06B+34.1%

Ionis PharmaceuticalsIONS

$370.24M+18.6%

Bristol-Myers SquibbBMY

$8.89B-15.3%

FAQ

What is Royalty Pharma's total costs & expenses?

Royalty Pharma (RPRX) reported total costs & expenses of $541.02M in Q2 2026.

How has Royalty Pharma's total costs & expenses changed year-over-year?

Royalty Pharma's total costs & expenses increased by 46.7% year-over-year, from $368.87M to $541.02M.

What is the long-term trend for Royalty Pharma's total costs & expenses?

Over 4 years (2021 to 2025), Royalty Pharma's total costs & expenses has grown at a -1.2% compound annual growth rate (CAGR), from $858.75M to $818.67M.

What does total costs & expenses mean?

This metric represents the aggregate sum of all operating and non-operating costs incurred by the company to support its business activities during a specific period. It encompasses expenses such as research and development funding, general and administrative overhead, and provisions for credit losses or changes in financial asset valuations. Monitoring this figure helps investors evaluate the company's overall cost structure and operational efficiency relative to its total revenue generation.